Roivant Sciences Ltd. ROIV
Institutional shares held
508 Million
1.26M
calls
2.52M
puts
Total value of holdings
$5.77B
$14.4M
calls
$28.6M
puts
Market Cap
$7.84B
704,382,976
Shares Out.
Institutional ownership
72.07%
# of Institutions
318
We take great care to ensure that the data presented and summarized in this overview for Roivant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ROIV
View all-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$734 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$732 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$602 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$464 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$394 Million0.01% of portfolio
-
Morgan Stanley New York, NY29.7MShares$330 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY22.4MShares$249 Million7.2% of portfolio
-
State Street Corp Boston, MA19.6MShares$218 Million0.01% of portfolio
-
Patient Square Capital LP Menlo Park, CA12.2MShares$136 Million52.38% of portfolio
-
Two Seas Capital LP Rye, NY9.72MShares$108 Million37.75% of portfolio
Latest Institutional Activity in ROIV
Top Purchases
Top Sells
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Transactions at ROIV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,896
-0.7%
|
$20,856
$11.15 P/Share
|
|
Jan 23
2025
|
Ilan Oren |
SELL
Payment of exercise price or tax liability
|
Direct |
313
-0.31%
|
$3,443
$11.21 P/Share
|
|
Jan 23
2025
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
2,386
+2.32%
|
-
|
|
Jan 23
2025
|
James C Momtazee |
SELL
Payment of exercise price or tax liability
|
Direct |
306
-0.32%
|
$3,366
$11.21 P/Share
|
|
Jan 23
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
1,248
+1.3%
|
-
|
|
Jan 23
2025
|
Epperly Melissa B, |
SELL
Payment of exercise price or tax liability
|
Direct |
180
-0.45%
|
$1,980
$11.21 P/Share
|
|
Jan 23
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,672
+4.04%
|
-
|
|
Jan 23
2025
|
Vivek Ramaswamy > 10% Shareholder |
BUY
Bona fide gift
|
Indirect |
13,357,857
+50.0%
|
-
|
|
Jan 23
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
13,357,857
-25.0%
|
-
|
|
Jan 21
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
100,000
-12.02%
|
$1,100,000
$11.28 P/Share
|
|
Jan 21
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+10.73%
|
$300,000
$3.85 P/Share
|
|
Jan 20
2025
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,623
-0.07%
|
$127,853
$11.15 P/Share
|
|
Jan 20
2025
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,682
-1.17%
|
$95,502
$11.15 P/Share
|
|
Jan 20
2025
|
Rakhi Kumar Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,057
-0.52%
|
$11,627
$11.15 P/Share
|
|
Dec 30
2024
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
177,704
-19.34%
|
$1,954,744
$11.54 P/Share
|
|
Dec 30
2024
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
250,000
+21.39%
|
$750,000
$3.85 P/Share
|
|
Dec 28
2024
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,896
-0.69%
|
$20,856
$11.8 P/Share
|
|
Dec 27
2024
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
176,900
-20.92%
|
$1,945,900
$11.82 P/Share
|
|
Dec 27
2024
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
250,000
+22.82%
|
$750,000
$3.85 P/Share
|
|
Dec 26
2024
|
Mayukh Sukhatme Pres&Chief Investment Officer |
SELL
Open market or private sale
|
Direct |
689,495
-3.53%
|
$8,273,940
$12.01 P/Share
|
Last 12 Months Summary
Buy / Acquisition
55M
Shares
From
15
Insiders
| Grant, award, or other acquisition | 36.4M shares |
|---|---|
| Exercise of conversion of derivative security | 5.22M shares |
| Bona fide gift | 13.4M shares |
Sell / Disposition
151M
Shares
From
27
Insiders
| Payment of exercise price or tax liability | 935K shares |
|---|---|
| Other acquisition or disposition | 126M shares |
| Open market or private sale | 10.2M shares |
| Grant, award, or other acquisition | 38.7K shares |
| Bona fide gift | 13.4M shares |